Dermatology · Philadelphia, PA
NPI
1124154554
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
3400 Civic Center Blvd, 1-330s Perelman Center
Philadelphia, PA, 19104
Phone (215) 662-2737
Groups this clinician bills Medicare through
Medicare paid, 2024
$76K
1,851 services
Medicare patients, 2024
376
Average age 73
Drug cost, 2024
$5.8M
1,258 prescriptions
Company payments, 2025
$193K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ruth Ann Vleugels was code 17003 (destruction skin lesion), 773 times for 144 patients. In total Ruth Ann Vleugels billed 1,851 services in 26 codes, and Medicare paid $76K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 773 | 144 | $1.69 | $1,305 |
| 99214 Office E&M - Established | Office | 527 | 337 | $77.90 | $41K |
| 17000 Destruction Skin Lesion | Office | 236 | 192 | $47.17 | $11K |
| 99215 Office E&M - Established | Office | 138 | 63 | $111.69 | $15K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 56 | 32 | $13.49 | $755 |
| 11102 Skin Biopsy | Office | 35 | 32 | $20.54 | $719 |
| 17004 Destruction Skin Lesion | Office | 32 | 24 | $79.29 | $2,537 |
By year: 2022 $83K for 1,985 services; 2023 $99K for 2,451 services; 2024 $76K for 1,851 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ruth Ann Vleugels prescribed most often to Medicare patients was Octagam (Immun Globg(Igg)/Malt/Iga Ov50), with 97 prescriptions and refills. In total Ruth Ann Vleugels wrote 1,258 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 97 | 97 | Under 11 | $2.1M |
| Methotrexate Methotrexate Sodium | 89 | 138 | 24 | $1,623 |
| Dupixent Syringe Dupilumab | 75 | 79 | Under 11 | $350K |
| Hydroxychloroquine Sulfate Generic | 70 | 150 | 21 | $2,799 |
| Panzyga Immun Glob G(Igg)-Ifas/Glycine | 58 | 68 | Under 11 | $968K |
| Mycophenolate Mofetil Generic | 50 | 79 | 12 | $7,705 |
| Dupixent Pen Dupilumab | 45 | 47 | Under 11 | $174K |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 43 | 44 | Under 11 | $454K |
| Ketoconazole Generic | 43 | 60 | 15 | $3,226 |
| Minoxidil Generic | 43 | 119 | 13 | $1,035 |
| Pentoxifylline Generic | 38 | 84 | 11 | $2,648 |
| Clobetasol Propionate Generic | 38 | 50 | 29 | $1,922 |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 34 | 34 | Under 11 | $314K |
| Triamcinolone Acetonide Generic | 32 | 41 | 25 | $345 |
| Betamethasone Dipropionate Generic | 31 | 36 | 15 | $2,202 |
Brand drugs: - claims; generic drugs: 722 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ruth Ann Vleugels $193K ($193K in general payments such as food, travel and fees) from 15 companies. The largest payer was Eli Lilly and Company with $51K.
| Company | Payments | Amount |
|---|---|---|
| Eli Lilly and Company LLY | 35 | $51K |
| Lilly USA, LLC LLY | 19 | $46K |
| AstraZeneca UK Limited AZN | 18 | $25K |
| Boehringer Ingelheim International GmbH | 3 | $16K |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $15K |
| Abbvie Inc. ABBV | 17 | $14K |
| Janssen Biotech, Inc. JNJ | 15 | $13K |
| Janssen Scientific Affairs, LLC JNJ | 1 | $5,860 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $2,325 |
| Pfizer Inc. PFE | 2 | $2,160 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.